Pharmacy World and Science

, Volume 25, Issue 5, pp 207–211 | Cite as

Determinants for successful smoking cessation with bupropion in daily practice

  • M.L. Bouvy
  • H. Buurma
  • A.C.G. Egberts


Objective: to describe the patterns of use of bupropion in daily clinical practice and factors which determine successful smoking cessation.Methods: Retrospective follow‐up study in 36 pharmacies in the Netherlands. Patients who received at least one prescription for bupropion between January and April, 2000 were included. The pharmacists noted several characteristics relating to the patient, use of bupropion and co‐medication. Patients were interviewed by telephone about their current and former smoking habits, the success of their smoking cessation and their experiences with bupropion.Main outcome measure: Abstinence rate and factors determining successful abstinence after six months.Results: 322 patients with a least one prescription for bupropion were identified. In 93.5% of patients bupropion was prescribed by the general practitioner. Half of the patients were dispensed 30 or fewer tablets. Pharmacists interviewed 215 (66.8%) patients by telephone. Of these patients 58 (27.0%) still did not smoke six months after the prescription for bupropion. The number of tablets used, lack of co‐morbidity, less than two previous attempts to stop smoking and private‐insurance were associated with a higher rate of successful abstinence. Conclusion: Most patients do not use bupropion in accordance with the recommended period and did not receive the same degree of additional support provided in clinical trials. Nevertheless 27.0% of patients reported to have stopped smoking six months after the prescription for bupropion. This self‐reported abstinence rate is only slightly lower than is reported in literature. This might be partly related to the fact that we did not validate smoking cessation by carbonmonoxide monitoring. Bupropion is not reimbursed in the Netherlands. It is difficult to assess whether patients' self‐payment has led to the selection of motivated patients, or has been a barrier to finishing using bupropion.

Bupropion Clinical practice Smoking cessation 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lancaster T, Stead L, Silagy C, Sowden A. Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. BMJ 2000; 321: 355–8.Google Scholar
  2. 2.
    Baillie AJ, Mattick RP, Hall W. Quitting smoking: estimation by meta-analysis of the rate of unaided smoking cessation. Aust J Public Health 1995; 19: 129–31.Google Scholar
  3. 3.
    Law M, Tang JL. An analysis of the effectiveness of interventions intended to help people stop smoking. Arch Intern Med 1995; 155: 1933–41.Google Scholar
  4. 4.
    Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation (Cochrane Review). Cochrane Database Syst Rev 2000; 4.Google Scholar
  5. 5.
    Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337: 1195–202.Google Scholar
  6. 6.
    Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685–91.Google Scholar
  7. 7.
    Muir J, Lancaster T Fowler G, Neil A. Community based heart health promotion project in England. Self reporting overestimates smoking cessation rates. BMJ 1998; 316: 704–5.Google Scholar
  8. 8.
    Osler M, Gerdes LU, Davidsen M, Bronnum-Hansen H, Madsen M, Jorgensen T et al. Socioeconomic status and trends in risk factors for cardiovascular diseases in the Danish MONICA population, 1982–1992. J Epidemiol Commun Health 2000; 54: 108–13.Google Scholar
  9. 9.
    Crampton P, Salmond C, Woodward A, Reid P. Socioeconomic deprivation and ethnicity are both important for anti-tobacco health promotion. Health Educ Behav 2000; 27: 317–27.Google Scholar
  10. 10.
    Connor SK, McIntyre L. The sociodemographic predictors of smoking cessation among pregnant women in Canada. Can J Public Health 1999; 90: 352–5.Google Scholar
  11. 11.
    Cavelaars AE, Kunst AE, Geurts JJ, Crialesi R, Grotvedt L, Helmert U et al. Educational differences in smoking: international comparison. BMJ 2000; 320: 1102–7.Google Scholar
  12. 12.
    Pierce JP, Gilpin EA. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA 2002; 288: 1260–4.Google Scholar
  13. 12.
    Ward KD, Klesges RC, Zbikowski SM, Bliss RE, Garvey AJ. Gender differences in the outcome of an unaided smoking cessation attempt. Addict Behav 1997; 22: 521–33.Google Scholar
  14. 13.
    Wee CC, Rigotti NA, Davis RB, Phillips RS. Relationship between smoking and weight control efforts among adults in the united states. Arch Intern Med 2001; 161: 546–50.Google Scholar

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  • M.L. Bouvy
    • 1
  • H. Buurma
    • 1
  • A.C.G. Egberts
    • 2
    • 3
  1. 1.SIR Institute for Pharmacy Practice ResearchLeidenThe Netherlands E‐mail
  2. 2.Department of Pharmacoepidemiology & PharmacotherapyUtrecht Institute for Pharmaceutical SciencesUtrechtThe Netherlands
  3. 3.TweeSteden and St. Elisabeth HospitalHospital Pharmacy Midden BrabantTilburgThe Netherlands

Personalised recommendations